CTOs on the Move

Clementia Pharmaceuticals

www.clementiapharma.com

 
Clementia is a biopharmaceutical company that is focused on exploiting the science of novel retinoic acid receptor gamma agonists to address bone disease. Our lead program is palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Clementia Pharmaceuticals raised $60M on 06/24/2015

Similar Companies

Athersys

Athersys is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DNA Direct

DNA Direct is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Calgary Scientific

Calgary Scientific is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chart Industries

Chart is a recognized global brand for the design and manufacture of highly engineered cryogenic equipment used from the beginning to the end in the liquid gas supply chain.

Gritstone Bio

Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics, immunotherapy and other precision therapy areas, specifically in COVID-19 and HIV. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system`s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.